LILA® is a new technology based on biophotonics wherein non-heat emitting highly pulsed nanosecond laser which when comes in contact with any tissue has the ability to eliminate only the C fibers (chronic pain nerves or the unmyelinated axons). Ablation takes place independent of any heat emissions through a subcellular mechanism called biophotonic ablation, wherein chronic pain nerves or unmyelinated axons are destroyed by laser absorption and self-destruction while leaving the surrounding tissues and non pain nerves intact. Biophotonic ablation is an evolving, innovative field of science wherein light is able to bring forth change in biological properties, in this case ablation or destruction of cells through laser modulation.

The resultant effect is immediate pain relief when used on pain generating anatomical areas along with the lack of adverse effects since non chronic pain nerves and normal tissues remain unaffected. The lack of myelin sheath makes the chronic pain nerves (also known as C-fibers) susceptible to the LILA® laser. The highly pulsed laser gets repetitively absorbed by the unmyelinated axons leading to their cellular destruction without any heat emissions. LILA® is therefore selective and has no adverse effects or side effects unlike heat emitting ablation devices that use laser or radiofrequency (RF).

PLEASE NOTE THAT THE LILA® DEVICE IS NOT INDICATED OR INTENDED TO TREAT OR DIAGNOSE ANY DISEASE OR A DISEASE CONDITION. IT IS A DEVICE THAT CAUSES LESIONS IN THE NERVOUS TISSUE LIMITED TO UNMYELINATED AXONS OR C FIBERS ONLY. PHYSICIANS DECIDE HOW TO USE A DEVICE. SUCH USE IS NOT DECIDED BY C LASER INC.

Low Intensity Laser Ablation or LILA® laser treatments are NOT approved by the FDA meaning that the safety and effectiveness documented by this device use has not been accepted by the FDA even after the device’s safety and effectiveness has been demonstrated in IRB approved clinical trial in patients, by real time video evidence and by real time evidence of safety and effectiveness in animals. The LILA® laser device remains ‘not FDA’ approved even after statistically exceeding the safety and effectiveness evidence provided by similar FDA approved devices in their pre-approval stage (or submissions). In fact no such comparable evidence is present even as of 2022 with any of the FDA approved drugs or devices used in the mitigation of pain. Experts have demonstrated that the LILA® laser selectively eliminates chronic pain nerve fibers also known as C-fibers or unmyelinated axons under electron microcopy examination while preserving the integrity of normal non chronic pain nerves and non neural elements such as micro-blood vessels. This type of selective ablation has NOT been demonstrated by any other device or drug including those that are FDA approved. LILA® laser has NOT shown to have any adverse effects or side effects in any and all evidence submitted to the FDA. For Inventor’s clinical demonstration please visit: https://inter-pain.com